BioLineRx declares partial results for BL-8040’s Phase 2a COMBAT study
BioLineRx, committed to oncology and immunology declared partial results from the monotherapy portion of BL-8040's Phase 2a COMBAT study. The study reveals that BL-8040 increases…
Read More...
Read More...